Drugs / PrEP-001

Trials 5 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT02243189 Oct → Dec 2014 asthma Janssen Research & Development, LLC Terminated No outcome recorded
Phase 23 trials
Phase 2 NCT03732547 Oct 2018 → Oct 2021 hepatocellular carcinoma Second Affiliated Hospital, School of Medicine, Zhejiang University Unknown No outcome recorded
Phase 2 NCT03296917 Dec 2015 → Sep 2016 asthma Hvivo Completed No outcome recorded
Phase 2 NCT03220048 Sep 2015 → Feb 2016 Hvivo Completed No outcome recorded
Phase 41 trial
Phase 4 NCT02532413 Jul 2015 → Aug 2016 chronic hepatitis B virus infection Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Unknown No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03198676 Comparator May 2017 respiratory tract infectious disorder Prep Biopharm Limited Completed No outcome recorded
Phase 21 trial
Phase 2 NCT03338556 Comparator Apr → Sep 2016 viral respiratory tract infection Prep Biopharm Limited Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as PrEP-001 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03198676
3

NCT03296917

NCT03220048

NCT03338556

Known as JNJ-43260295 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02243189
Known as Poly IC ClinicalTrials.gov intervention name — accepted as the source's own label NCT02532413
1

NCT03732547

Route Intranasal “A single nasal dose of JNJ-43260295, 6400 microgram, will be given.” NCT02243189